Targeting tumours with genetically enhanced T lymphocytes
Top Cited Papers
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 3 (1), 35-45
- https://doi.org/10.1038/nrc971
Abstract
The genetic modification of T lymphocytes is an important approach to investigating normal T-cell biology and to increasing antitumour immunity. A number of genetic strategies aim to increase the recognition of tumour antigens, enhance antitumour activities and prevent T-cell malfunction. T cells can also be engineered to increase safety, as well as to express markers that can be tracked by non-invasive imaging technologies. Genetically modified T cells are therefore proving to be of great value for basic immunology and experimental immunotherapy.Keywords
This publication has 119 references indexed in Scilit:
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Retroviral Transduction of a T Cell Receptor Specific for an Epstein–Barr Virus-Encoded PeptideClinical Immunology, 2001
- Role of transforming growth factor beta in cancerJournal of Cellular Physiology, 2001
- Impact of chimeric immune receptor extracellular protein domains on T cell functionGene Therapy, 1999
- REGULATION OF IMMUNE RESPONSES BY TGF-βAnnual Review of Immunology, 1998
- Cancer Tumor antigensCurrent Opinion in Immunology, 1997
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptidesCell, 1991
- The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathwaysCell, 1991